Ductal Carcinoma in Situ Clinical Trials

10 recruiting

Ductal Carcinoma in Situ Trials at a Glance

16 actively recruiting trials for ductal carcinoma in situ are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Not Applicable with 7 trials, with the heaviest enrollment activity in Tampa, Philadelphia, and Gainesville. Lead sponsors running ductal carcinoma in situ studies include Thomas Jefferson University, University of Florida, and Finn, Olivera, PhD.

Browse ductal carcinoma in situ trials by phase

Treatments under study

About Ductal Carcinoma in Situ Clinical Trials

Looking for clinical trials for Ductal Carcinoma in Situ? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ductal Carcinoma in Situ trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ductal Carcinoma in Situ clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 2

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Ductal Carcinoma in Situ
University of Florida30 enrolled1 locationNCT06868238
Recruiting
Phase 2

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Ductal Carcinoma in Situ
QuantumLeap Healthcare Collaborative400 enrolled27 locationsNCT06075953
Recruiting
Not Applicable

Endoscopic Nipple-Sparing Mastectomy Through a Single Axillary Incision in Breast Cancer

Breast CancerBreast Cancer - Ductal Carcinoma in Situ (DCIS)
Fondazione del Piemonte per l'Oncologia10 enrolled1 locationNCT07507890
Recruiting
Phase 1

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Ductal Carcinoma in Situ
Finn, Olivera, PhD50 enrolled1 locationNCT06218303
Recruiting
Not Applicable

A Patient Navigation Program for Addressing Disparities in Breast Cancer Care

Breast CarcinomaBreast Ductal Carcinoma in Situ
Roswell Park Cancer Institute126 enrolled1 locationNCT06350500
Recruiting
Not Applicable

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Anatomic Stage 0 Breast Cancer AJCC v8Invasive Breast CarcinomaAnatomic Stage 1 Breast Cancer AJCC v8+3 more
Thomas Jefferson University80 enrolled1 locationNCT04959474
Recruiting

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

Breast Cancer FemaleBreast Cancer DetectionBreast Cancer Early Stage Breast Cancer (Stage 1-3)+4 more
Oncoliq US Inc300 enrolled1 locationNCT07331506
Recruiting
Not Applicable

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

Breast CancerDuctal Carcinoma in Situ
University of Florida50 enrolled1 locationNCT06903468
Recruiting
Not Applicable

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Ductal Carcinoma in SituStage III Breast CancerStage I Breast Cancer+1 more
Barbara Ann Karmanos Cancer Institute30 enrolled1 locationNCT07095114
Recruiting
Not Applicable

Neoadjuvant Breast Cancer Time Restricted Eating

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Thomas Jefferson University55 enrolled1 locationNCT05327608
Recruiting
Phase 2

Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer

Breast CancerDuctal Carcinoma in SituInvasive Breast Cancer
Yonsei University47 enrolled1 locationNCT06677944
Recruiting
Not Applicable

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ

Ductal Carcinoma in Situ
Glendale Adventist Medical Center d/b/a Adventist Health Glendale30 enrolled1 locationNCT05218044
Recruiting

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

Ductal Carcinoma in SituInvasive Ductal Carcinoma of Female Breast
RPCR, Inc.200 enrolled2 locationsNCT04985032
Recruiting
Phase 2

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ

Ductal Carcinoma in SituExtensive DiseaseMastectomy
Institut Cancerologie de l'Ouest262 enrolled8 locationsNCT04666961
Recruiting

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with Ductal Carcinoma In Situ (DCIS) Following Breast Conserving Therapy to Determine the Clinical Utility of the DCISionRT Test in the Management of DCIS

Ductal carcinoma in situ (DCIS) of the breast
Prelude Australia Pty Limited1,500 enrolled9 locationsACTRN12621000695808
Recruiting

Can contrast enhanced spectral mammography (CESM) play a clinically useful role in the pre-operative assessment of women with Ductal Carcinoma in Situ (DCIS), the ‘CESM D’ study

Ductal Carcinoma in Situ
Clin. Assoc. Prof. Donna Taylor60 enrolled1 locationACTRN12616001696482